TLR9 and rheumatoid arthritis: For example, Li et al. [24] demonstrated that blocking FcRL3 with specific monoclonal antibodies reduces B-cell activation in response to TLR9, lowering both proliferation and antibody production, and thereby suggesting potential clinical utility for controlling excessive humoral responses in RA.